Aisling Capital IV, LP - Jun 24, 2021 Form 3 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
10%+ Owner
Signature
AISLING CAPITAL IV, LP, by Aisling Capital Partners IV, LP, its General Partner, by Aisling Capital Partners IV LLC, its General Partner, /s/ Andrew Schiff, Managing Member
Stock symbol
ELEV
Transactions as of
Jun 24, 2021
Transactions value $
$0
Form type
3
Date filed
6/24/2021, 06:32 PM
Next filing
Jul 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ELEV Common Stock 296K Jun 24, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ELEV Series A Preferred Stock Jun 24, 2021 Common Stock 1.89M Direct F1, F2
holding ELEV Series B Preferred Stock Jun 24, 2021 Common Stock 458K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.
F2 The shares of the Issuer's Preferred Stock will automatically convert on a 4.225582-for-one basis into the number of shares of the issuer's Common Stock shown in column 3 immediately upon the closing of the issuer's initial public offering, and has no expiration date.